Literature DB >> 1307003

[Usefulness of the ELISA-IgG test in sera and filter paper blood eluates in the Chagas disease immunodiagnosis].

M C Contreras1, P Salinas, L Sandoval, F Solís, A Rojas.   

Abstract

An ELISA-IgG test using a soluble extract of Trypanosoma cruzi antigen has been developed. One hundred and seventy eight sera (74 healthy people, 44 chagasic patients with positive xenodiagnosis and 60 with clinical symptoms), and 64 paper filter blood eluates (35 healthy people, 10 chagasic patients and 19 with clinical symptoms) were tested by ELISA-IgG and an indirect hemagglutination test. Both types of methods presented an overall average concordance of 98.3% and 100.0% with sera and filter paper blood eluates respectively. A cut off (average of optical density plus 3 standard deviations) of 0.365 and 0.379 for sera and eluates was found. The use of ELISA-IgG in Chagas' disease clinical diagnosis and seroepidemiological studies is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1307003

Source DB:  PubMed          Journal:  Bol Chil Parasitol        ISSN: 0365-9402


  3 in total

1.  Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs.

Authors:  Africa Holguín; Francesca Norman; Leticia Martín; María Luisa Mateos; Jesús Chacón; Rogelio López-Vélez; José A Pérez-Molina
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

2.  Lateral flow immunoassay for diagnosis of Trypanosoma cruzi infection with high correlation to the radioimmunoprecipitation assay.

Authors:  Raymond L Houghton; Yvonne Y Stevens; Kathryn Hjerrild; Jeff Guderian; Masahiko Okamoto; Mazbahul Kabir; Steven G Reed; David A Leiby; W John W Morrow; Myriam Lorca; Syamal Raychaudhuri
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

Review 3.  ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.

Authors:  Pedro E A A Brasil; Liane De Castro; Alejandro M Hasslocher-Moreno; Luiz H C Sangenis; José U Braga
Journal:  BMC Infect Dis       Date:  2010-11-25       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.